QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.119040v1 322/2/486    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chapman, R. W. Articles by Hey, J. A. Search for Related Content PubMed PubMed Citation Articles by Chapman, R. W. Articles by Hey, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Bronchitis Hazardous Substances DB CYCLOBUTANE VANADIUM COMPOUNDS VANADIUM PENTOXIDE

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary Inflammation

Departments of Pulmonary and Peripheral Neurobiology (R.W.C., M.M., C.S.C., J.E.P., T.T.K., M.M.B. J.A.H.), Inflammation (R.W.H., X.F., G.D., W.G., J.S.F.), Drug Metabolism and Pharmacokinetics (D.R.), and Tumor Biology (R.B.), Discovery Research, Schering-Plough Research Institute, Kenilworth, New Jersey

Sch527123 [2-hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]ben-zamide] is a potent, selective antagonist of the human CXCR1 and CXCR2 receptors (Gonsiorek et al., 2007). Here we describe its pharmacologic properties at rodent CXCR2 and at the CXCR1 and CXCR2 receptors in the cynomolgus monkey, as well as its in vivo activity in models demonstrating prominent pulmonary neutrophilia, goblet cell hyperplasia, and mucus production. Sch527123 bound with high affinity to the CXCR2 receptors of mouse (K_d = 0.20 nM), rat (K_d = 0.20 nM), and cynomolgus monkey (K_d = 0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC₅₀ 3–6 nM). In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (K_d = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC₅₀ 1000 nM). Oral treatment with Sch527123 blocked pulmonary neutrophilia (ED₅₀ = 1.2 mg/kg) and goblet cell hyperplasia (32–38% inhibition at 1–3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration. In rats, Sch527123 suppressed the pulmonary neutrophilia (ED₅₀ = 1.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED₅₀ =<0.1 mg/kg) induced by intratracheal (i.t.) LPS. Sch527123 also suppressed the pulmonary neutrophilia (ED₅₀ = 1.3 mg/kg), goblet cell hyperplasia (ED₅₀ = 0.7 mg/kg), and increase in BAL mucin content (ED₅₀ = <1 mg/kg) in rats after i.t. administration of vanadium pentoxide. In cynomolgus monkeys, Sch527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED₅₀ = 0.3 mg/kg). Therefore, Sch527123 may offer benefit for the treatment of inflammatory lung disorders in which pulmonary neutrophilia and mucus hypersecretion are important components of the underlying disease pathology.

Address correspondence to: Dr. Richard W. Chapman, Schering Plough Research Institute, Pulmonary and Peripheral Neurobiology, 2015 Galloping Hill Rd, K-15-1650, Kenilworth, NJ 07033. E-mail: richard.chapman{at}spcorp.com

This article has been cited by other articles:

				W. Gonsiorek, X. Fan, D. Hesk, J. Fossetta, H. Qiu, J. Jakway, M. Billah, M. Dwyer, J. Chao, G. Deno, et al. Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 477 - 485. [Abstract] [Full Text] [PDF]